V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Regeneron Pharmaceuticals Executive Compensation (FY25)

REGN · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): June 17, 2026
259 figures on this page: 252 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Leonard Schleifer was paid $7,280,549 in total compensation as Board co-Chair, President and Chief Executive Officer for fiscal 2025, and Schleifer's total was 6.7% higher than the $6,823,034 reported for fiscal 2024. Separately, the disclosed chief executive pay ratio for fiscal 2025 is 42:1, against median employee compensation of $174,138. Meanwhile, for fiscal 2025, shareholders backed the say-on-pay proposal with 93.3% of votes cast for or against in favor at the meeting held June 12, 2026. The disclosed peer group includes AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., Biogen Inc. and BioMarin Pharmaceutical Inc., among others.
Chief executive, fiscal 2025
◇
Leonard Schleifer
Median of the other named officers
$7,458,970
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 12, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Leonard Schleifer: $6,823,034 → $7,280,549 (6.7% higher)
CEO pay ratio: 41:1 → 42:1 (2.4% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Regeneron Pharmaceuticals' chief executive and what were they paid?
Leonard Schleifer was paid $7,280,549 in total compensation as Board co-Chair, President and Chief Executive Officer for fiscal 2025. Schleifer's total was 6.7% higher than the $6,823,034 reported for fiscal 2024.
What was Regeneron Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 93.3% of votes cast for or against in favor at the meeting held June 12, 2026.
Which companies are in Regeneron Pharmaceuticals' peer group?
The disclosed peer group includes AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., Biogen Inc. and BioMarin Pharmaceutical Inc., among others.
What is Regeneron Pharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 42:1, against median employee compensation of $174,138.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Andrew Murphy
Executive Vice President, Co-Chief Scientific Officer
◇—◇◇◇—◇◇
Daniel Van Plew
Executive Vice President and General Manager, Industrial Operations and Product Supply
◇—◇◇◇—◇◇
Robert Landry
Former Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇—◇◇
Leonard Schleifer
Board co-Chair, President and Chief Executive Officer
◇———◇—◇◇
George Yancopoulos
Board co-Chair, President and Chief Scientific Officer
◇———◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel Van Plew
Executive Vice President and General Manager, Industrial Operations and Product Supply
◇—◇◇◇—◇◇
Andrew Murphy
Executive Vice President, Co-Chief Scientific Officer
◇—◇◇◇—◇◇
Leonard Schleifer
Board co-Chair, President and Chief Executive Officer
◇———◇—◇◇
George Yancopoulos
Board co-Chair, President and Chief Scientific Officer
◇———◇—◇◇
Robert Landry
Former Executive Vice President, Finance and Chief Financial Officer
◇———◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel Van Plew
Executive Vice President and General Manager, Industrial Operations and Product Supply
◇—◇◇◇—◇◇
Andrew Murphy
Executive Vice President, Co-Chief Scientific Officer
◇—◇◇◇—◇◇
Leonard Schleifer
Board co-Chair, President and Chief Executive Officer
◇———◇—◇◇
George Yancopoulos
Board co-Chair, President and Chief Scientific Officer
◇———◇—◇◇
Christopher Fenimore
Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇—◇◇
Robert Landry
Former Executive Vice President, Finance and Chief Financial Officer
Departed during or after this year
◇—————◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Daniel Van Plew
Executive Vice President and General Manager, Industrial Operations and Product Supply
◇—◇◇◇—◇◇
Andrew Murphy
Executive Vice President, Co-Chief Scientific Officer
◇—◇◇◇—◇◇
Joseph LaRosa
Executive Vice President, General Counsel and Secretary
◇◇◇◇◇—◇◇
Leonard Schleifer
Board co-Chair, President and Chief Executive Officer
◇———◇—◇◇
Christopher Fenimore
Executive Vice President, Finance and Chief Financial Officer
◇—◇◇◇—◇◇
George Yancopoulos
Board co-Chair, President and Chief Scientific Officer
◇———◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew MurphyRSU◇——◇——◇
Andrew MurphyOPTION◇——◇—◇◇
Christopher FenimoreRSU◇——◇——◇
Christopher FenimoreOPTION◇——◇—◇◇
Daniel Van PlewRSU◇——◇——◇
Daniel Van PlewOPTION◇——◇—◇◇
Joseph LaRosaOPTION◇——◇—◇◇
Joseph LaRosaRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Joseph LaRosaRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Andrew MurphyRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Christopher FenimoreRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christine A. Poon
Lead independent director
◇◇◇——◇◇
Michael S. Brown
◇◇◇——◇◇
George L. Sing
◇◇◇——◇◇
Arthur F. Ryan
◇◇◇——◇◇
Huda Y. Zoghbi
◇◇◇——◇◇
N. Anthony Coles
◇◇◇——◇◇
Joseph L. Goldstein
◇◇◇——◇◇
Craig B. Thompson
◇◇◇——◇◇
David P. Schenkein
◇◇◇——◇◇
Bonnie L. Bassler, Kathryn Guarini, George D. Yancopoulos and Leonard S. Schleifer served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Equity is delivered as Stock Options (80%) and RSUs (20%).

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbbVie Inc. ABBV
  • Alnylam Pharmaceuticals, Inc. ALNY
  • Amgen Inc. AMGN
  • Biogen Inc. BIIB
  • BioMarin Pharmaceutical Inc. BMRN
  • Bristol-Myers Squibb Company BMY
  • Eli Lilly and Company LLY
  • Gilead Sciences, Inc. GILD
  • Incyte Corporation INCY
  • Merck & Co., Inc. MRK
  • Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 12, 2026=◇◇◇
2024June 13, 2025=◇◇◇
2023June 14, 2024=◇◇◇
2022June 9, 2023=◇◇◇
2021June 10, 2022=◇◇◇
2019June 12, 2020=◇◇◇
2016June 9, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Regeneron Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Regeneron Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Regeneron Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Regeneron Pharmaceuticals' disclosed peer group is defensible, who names Regeneron Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
259 figures on this page: 252 cited to the filing that reported them, 7 calculated from figures it prints.
252 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001104659-26-075127
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001308179-26-000340
    2025 Director Compensation · 2025 Grants of Plan-Based Awards · 2025 Summary Compensation Table · Director Compensation · and 2 more sections
  3. 0001104659-25-060637
  4. 0001308179-25-000518
    2024 Summary Compensation Table
  5. 0001104659-25-030590
    Table 2: 2024 Grants of Plan-Based Awards
  6. 0001104659-24-073372
  7. 0001308179-24-000577
    2023 Summary Compensation Table
  8. 0001104659-23-071187
  9. 0001308179-23-000728
    2022 Summary Compensation Table · Summary Compensation Table
  10. 0001104659-22-071446
  11. 0001104659-20-073794
  12. 0001104659-17-039157
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Regeneron Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/REGN (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Regeneron Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Regeneron Pharmaceuticals discloses

The companies named in REGN's own disclosed peer group.

AbbVie Inc.Alnylam Pharmaceuticals, Inc.Amgen Inc.Biogen Inc.BioMarin Pharmaceutical Inc.Bristol-Myers Squibb CompanyEli Lilly and CompanyGilead Sciences, Inc.Incyte CorporationMerck & Co., Inc.Vertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy